1. Home
  2. NUWE vs PTIX Comparison

NUWE vs PTIX Comparison

Compare NUWE & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuwellis Inc.

NUWE

Nuwellis Inc.

HOLD

Current Price

$2.06

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Logo Protagenic Therapeutics Inc.

PTIX

Protagenic Therapeutics Inc.

HOLD

Current Price

$1.15

Market Cap

3.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUWE
PTIX
Founded
1999
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
3.0M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
NUWE
PTIX
Price
$2.06
$1.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
47.0K
104.5K
Earning Date
11-12-2025
11-26-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,167,999.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.02
$1.17
52 Week High
$70.14
$14.28

Technical Indicators

Market Signals
Indicator
NUWE
PTIX
Relative Strength Index (RSI) 39.14 22.92
Support Level $2.02 $1.17
Resistance Level $2.35 $1.68
Average True Range (ATR) 0.18 0.13
MACD -0.01 -0.02
Stochastic Oscillator 4.76 4.39

Price Performance

Historical Comparison
NUWE
PTIX

About NUWE Nuwellis Inc.

Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.

About PTIX Protagenic Therapeutics Inc.

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Share on Social Networks: